Nov 08, 2022 / 07:00PM GMT
Norman D. Schwartz - Bio-Rad Laboratories, Inc. - Chairman, CEO & President
(technical difficulty)
With all the kind of muscle building we've done internally that we are better positioned to do something maybe more meaningful in terms of size. Now I think there's some -- maybe some confusion about what that means. And just to make sure that people understand that at the end of the day, we think about our debt capacity. And we think about, okay, what's the size of something we could reasonably do today given that debt capacity. And that's probably in the, say, the $4 billion to $5 billion range if we levered up. Obviously, with the idea that we would want to delever fairly rapidly. We don't want to carry that high debt for a long period of time.
And then the question is use of equity. Given where Bio-Rad's share price is today, it probably is much less likely that we would use equity. There's always a possibility of using equity to maybe top up something, maybe a small amount of equity to top up something. Or if there was something that we were acquiring that was equally undervalued,
Bio Rad Laboratories Inc at Credit Suisse Healthcare Conference Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers